From friction to compliance: Cultivating seamless operations in a shifting regulatory landscape
2026 has brought a plethora of converging technological change and regulatory updates to the life sciences industry at an unprecedented…
Partner Content
-
-
Central, local, or hybrid? Designing smarter depot strategies for clinical trials
The design of depot strategy has long been framed as a fundamental trade-off within the clinical trial supply chain. Sponsors…
-
Five considerations for adopting AI in clinical study build workflows
Artificial intelligence (AI) is becoming widely adopted in clinical data management, but the most persuasive use cases are rarely the…
-
Biomarkers in Nephrology Research: From Exploratory to Decision-Making Tools
While strategic use of biomarkers in clinical trials has traditionally been associated with oncology, the potential for growth across other…
-
Is your quality system built for 2026’s new regulatory reality?
The life sciences industry has always operated under pressure to stay ahead of regulatory change. But 2026 has raised the…
-
Keeping pace with generative AI in pharmaceutical and healthcare organisations
Increasingly, generative AI is transforming how that information is analysed, summarised and shared. According to 2026 research by the Copyright…
-
Improving cardiometabolic trial execution: Key insight for sponsors
“Nothing can ruin your study faster than if your volunteers are not compliant and you can’t retain them.” This was…
-
Early Biomarkers as Predictors of Nephrology Trial Trajectory
Chronic kidney disease (CKD) and other nephrology conditions are a major global health challenge. With rising prevalence and persistent unmet…
-
From collection to confidence: why clinical trial data reliability starts early
Every sponsor decision, from dose selection to portfolio prioritisation, depends on whether the evidence generated in a trial is based…
-
Post-marketing oncology studies: Enabling faster recruitment and lower costs
Post-marketing approval studies in clinical research for cancer typically suffer from poor engagement and protracted timelines – driving up costs…